Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Status:
Recruiting
Trial end date:
2031-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with
rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or
Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.